|
|
 |
29 |
 |
| |
Issues in chronic myocardial ischemia treatment
|
|
 |
|
 |
|
|
30 |
|
| |
Stable CAD: Multiple treatment options
|
|
|
|
|
|
|
31 |
|
| |
SAFE-LIFE: Evaluation of intensive lifestyle intervention
|
|
|
|
|
|
|
32 |
|
| |
SAFE-LIFE: Reduction in angina at 1 year with intensive lifestyle intervention
|
|
|
|
|
|
|
33 |
|
| |
Chronic ischemic heart disease: Treatment gaps
|
|
|
|
|
|
|
34 |
|
| |
Novel anti-ischemic strategy
|
|
|
|
|
|
|
35 |
|
| |
Ranolazine clinical trial program
|
|
|
|
|
|
|
36 |
|
| |
Ranolazine clinical trial program in chronic stable angina
|
|
|
|
|
|
|
37 |
|
| |
MARISA, CARISA, ERICA main findings
|
|
|
|
|
|
|
38 |
|
| |
Challenges in selected populations: Experience with ranolazine
|
|
|
|
|
|
|
39 |
|
| |
Antianginal efficacy by gender
|
|
|
|
|
|
|
40 |
|
| |
Antianginal efficacy by gender
|
|
|
|
|
|
|
41 |
|
| |
Antianginal efficacy by age
|
|
|
|
|
|
|
42 |
|
| |
Antianginal efficacy by diabetes status
|
|
|
|
|
|
|
43 |
|
| |
CARISA: Reductions in A1C (diabetes substudy)
|
|
|
|
|
|
|
44 |
|
| |
Summary: Ranolazine in challenging populations
|
|
|
|
|
|
|
45 |
|
| |
ROLE: Long-term safety and tolerability in stable CAD patients
|
|
|
|
|
|
|
46 |
|
| |
MERLIN-TIMI 36: Study design
|
|
|
|
|
|
|
47 |
|
| |
MERLIN-TIMI 36: Effect on primary endpoint
|
|
|
|
|
|
|
48 |
|
| |
MERLIN-TIMI 36: Components of primary endpoint
|
|
|
|
|
|
|
49 |
|
| |
MERLIN-TIMI 36: Efficacy results in major subgroups
|
|
|
|
|
|
|
50 |
|
| |
MERLIN-TIMI 36: Primary arrhythmia endpoints
|
|
|
|
|
|
|
51 |
|
| |
MERLIN-TIMI 36: Reduction in VT lasting 8 beats or more
|
|
|
|
|
|
|
52 |
|
| |
MERLIN-TIMI 36: Incidence of VT = 8 beats or more in high-risk subgroups
|
|
|
|
|
|
|
53 |
|
| |
MERLIN-TIMI 36: Ventricular tachycardia events
|
|
|
|
|
|
|
54 |
|
| |
MERLIN-TIMI 36: Major safety outcomes
|
|
|
|
|
|
|
55 |
|
| |
MERLIN-TIMI 36: Sudden cardiac death by subgroup
|
|
|
|
|
|
|
56 |
|
| |
MERLIN-TIMI 36: Summary and implications
|
|
|
|
|
|
|
57 |
|
| |
Stable CAD: Multiple treatment options
|
|
|
|
|
|
|
|
|
59 |
|
| |
ACIP: Baseline characteristics
|
|
|
|
|
|
|
60 |
|
| |
ACIP: Two-year cumulative all-cause mortality rates for the treatment strategies
|
|
|
|
|
|
|
61 |
|
| |
SWISSI II: Study design
|
|
|
|
|
|
|
62 |
|
| |
SWISSI II: Baseline characteristics
|
|
|
|
|
|
|
63 |
|
| |
SWISSI II: Treatment effect on primary outcome
|
|
|
|
|
|
|
64 |
|
| |
ACIP, SWISSI II: Summary and implications
|
|
|
|
|
|
|
65 |
|
| |
COURAGE: Defining optimal care
|
|
|
|
|
|
|
66 |
|
| |
What is the definitive role of PCI in chronic angina and stable CAD?
|
|
|
|
|
|
|
67 |
|
| |
Patient expectations about elective PCI for stable CAD
|
|
|
|
|
|
|
|
|
69 |
|
| |
COURAGE: Lifestyle intervention and risk factor goals
|
|
|
|
|
|
|
70 |
|
| |
COURAGE: Pharmacologic therapy
|
|
|
|
|
|
|
71 |
|
| |
COURAGE: Baseline angiographic data
|
|
|
|
|
|
|
72 |
|
| |
COURAGE: Baseline angina
|
|
|
|
|
|
|
73 |
|
| |
COURAGE: Inducible ischemia at baseline
|
|
|
|
|
|
|
74 |
|
| |
COURAGE: Treatment effect on primary outcome
|
|
|
|
|
|
|
75 |
|
| |
COURAGE: Treatment effect on angina
|
|
|
|
|
|
|
76 |
|
| |
COURAGE: Treatment effect in CV and diabetes subgroups
|
|
|
|
|
|
|
77 |
|
| |
COURAGE: Change in quality-of-life scores
|
|
|
|
|
|
|
78 |
|
| |
COURAGE: Summary and implications
|
|
|
|
|
|
|
Resources
